Iron chelation therapy with deferiprone improves oxidative status and red blood cell quality and reduces redox-active iron in β-thalassemia/hemoglobin E patients

Iron chelation therapy with deferiprone improves oxidative status and red blood cell quality and reduces redox-active iron in β-thalassemia/hemoglobin E patients

The oxidative status of twenty-three β-thalassemia/hemoglobin E patients was evaluated after administration of 75 mg/kg deferiprone (GPO-L-ONE®) divided into 3 doses daily for 12 months. Serum ferritin was significantly decreased; the median value at the initial and final assessments was 2842 and 17...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Noppawan Phumala Morales, Supot Rodrat, Pannaree Piromkraipak, Paveena Yamanont, Kittiphong Paiboonsukwong, Suthat Fucharoen
Formato: article
Lenguaje:EN
Publicado: Elsevier 2022
Materias:
Deferiprone
Redox-active iron
Oxidative stress
Spin-labeling
Spin-trapping
β-thalassemia
Therapeutics. Pharmacology
RM1-950
Acceso en línea:https://doaj.org/article/7672ec8198024ba987095f6f0446c910
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/7672ec8198024ba987095f6f0446c910

Ejemplares similares